By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "The TMPRSS2/ERG (T/E) fusion gene is present in half of all prostate cancer tumors. Fusion of the oncogenic ERG gene with the androgen-regulated TMPRSS2 gene promoter results in expression of fusion mRNAs in prostate cancer cells."
Our news journalists obtained a quote from the research from the Baylor University College of Medicine, "The junction of theTMPRSS2-and ERG-derived portions of the fusion mRNA constitutes a cancer-specific target in cells containing the T/E fusion gene. Targeting the most common alternatively spliced fusion gene mRNA junctional isoforms in vivo using siRNAs in liposomal nanovectors may potentially be a novel, low-toxicity treatment for prostate cancer. We designed and optimized siRNAs targeting the two most common T/E fusion gene mRNA junctional isoforms (type III or type VI). Specificity of siRNAs was assessed by transient co-transfection in vitro. To test their ability to inhibit growth of prostate cancer cells expressing these fusion gene isoforms in vivo, specific siRNAs in liposomal nanovectors were used to treat mice bearing orthotopic or subcutaneous xenograft tumors expressing the targeted fusion isoforms. The targeting siRNAs were both potent and highly specific in vitro. In vivo they significantly inhibited tumor growth. The degree of growth inhibition was variable and was correlated with the extent of fusion gene knockdown. The growth inhibition was associated with marked inhibition of angiogenesis and, to a lesser degree, proliferation and a marked increase in apoptosis of tumor cells. No toxicity was observed."
According to the news editors, the research concluded: "Targeting the T/E fusion junction in vivo with specific siRNAs delivered via liposomal nanovectors is a promising therapy for men with prostate cancer."
For more information on this research see: Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clinical Cancer Research, 2012;18(24):6648-57. Clinical Cancer Research can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research - www.aacr.com; Clinical Cancer Research - clincancerres.aacrjournals.org/)
The news correspondents report that additional information may be obtained from L. Shao, Dept. of Pathology and Immunology and Michael E DeBakey Dept. of Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas 77030, United States. Additional authors for this research include I. Tekedereli, J. Wang, E. Yuca, S. Tsang, A. Sood, G. Lopez-Berestein, B. Ozpolat and M. Ittmann (see also Biotechnology).
The publisher's contact information for the journal Clinical Cancer Research is: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.
Keywords for this news article include: Biotechnology, Texas, Houston, Oncology, Liposomes, United States, Prostate Cancer, Cancer Gene Therapy, Prostatic Neoplasms, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC